<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">Favipiravir has a broad spectrum of activity toward RNA viruses, including life-threatening RNA viruses, and exhibits efficacy in animal models of these infections. 
 <xref rid="t0005" ref-type="table">Table 1</xref> summarizes the efficacy of favipiravir in animal models of human infections. Based on the efficacy in animal models, it has been used to treat humans with diseases such as Ebola virus infection (
 <xref rid="bb0030" ref-type="bibr">Bai et al., 2016</xref>; 
 <xref rid="bb0265" ref-type="bibr">Jacobs et al., 2015</xref>; 
 <xref rid="bb0540" ref-type="bibr">Sissoko et al., 2016</xref>), Lassa fever (
 <xref rid="bb0465" ref-type="bibr">Raabe et al., 2017</xref>), norovirus (
 <xref rid="bb0480" ref-type="bibr">Ruis et al., 2018</xref>), and rabies (
 <xref rid="bb0035" ref-type="bibr">Baker, 2017</xref>). Notably, as a broad spectrum anti-RNA virus drug, favipiravir has been submitted for additional indications for SFTS in Japan, based on clinical trials (
 <xref rid="bb0645" ref-type="bibr">Yasukawa, 2016</xref>).
</p>
